[go: up one dir, main page]

WO2006015369A3 - Dosage d'identification d'inhibiteurs de topoisomerase - Google Patents

Dosage d'identification d'inhibiteurs de topoisomerase Download PDF

Info

Publication number
WO2006015369A3
WO2006015369A3 PCT/US2005/027605 US2005027605W WO2006015369A3 WO 2006015369 A3 WO2006015369 A3 WO 2006015369A3 US 2005027605 W US2005027605 W US 2005027605W WO 2006015369 A3 WO2006015369 A3 WO 2006015369A3
Authority
WO
WIPO (PCT)
Prior art keywords
assays
identification
topoisomerase inhibitors
topoisomerase
provides
Prior art date
Application number
PCT/US2005/027605
Other languages
English (en)
Other versions
WO2006015369A2 (fr
WO2006015369A9 (fr
Inventor
James T Stivers
Keehwan Kwon
Original Assignee
Univ Johns Hopkins
James T Stivers
Keehwan Kwon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins, James T Stivers, Keehwan Kwon filed Critical Univ Johns Hopkins
Publication of WO2006015369A2 publication Critical patent/WO2006015369A2/fr
Publication of WO2006015369A9 publication Critical patent/WO2006015369A9/fr
Priority to US11/701,981 priority Critical patent/US20080020973A1/en
Publication of WO2006015369A3 publication Critical patent/WO2006015369A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/533—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving isomerase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un dosage spectroscopique continu de l'activité topoisomérase d'ADN. Cette invention concerne aussi des inhibiteurs de topoisomérase et des compositions pharmaceutiques destinées au traitement des maladies et ses troubles associés à la topoisomérase.
PCT/US2005/027605 2004-08-03 2005-08-03 Dosage d'identification d'inhibiteurs de topoisomerase WO2006015369A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/701,981 US20080020973A1 (en) 2004-08-03 2007-02-01 Assays for identification of topoisomerase inhibitors

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US59839504P 2004-08-03 2004-08-03
US60/598,395 2004-08-03
US59839804P 2004-08-08 2004-08-08
US60/598,398 2004-08-08
US69325205P 2005-06-23 2005-06-23
US60/693,252 2005-06-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/701,981 Continuation US20080020973A1 (en) 2004-08-03 2007-02-01 Assays for identification of topoisomerase inhibitors

Publications (3)

Publication Number Publication Date
WO2006015369A2 WO2006015369A2 (fr) 2006-02-09
WO2006015369A9 WO2006015369A9 (fr) 2006-03-30
WO2006015369A3 true WO2006015369A3 (fr) 2009-04-16

Family

ID=35787925

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/027605 WO2006015369A2 (fr) 2004-08-03 2005-08-03 Dosage d'identification d'inhibiteurs de topoisomerase

Country Status (1)

Country Link
WO (1) WO2006015369A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007146375A2 (fr) * 2006-06-14 2007-12-21 Government Of The United States Of America, As Represented By The Secretary Department Of Health And Human Services Composés de pyrimido-dione-quinoléine hautement solubles et procédés de traitement du cancer
WO2008124145A1 (fr) * 2007-04-05 2008-10-16 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Composés stéroïdes, compositions et procédés de traitement
WO2012036573A2 (fr) * 2010-09-14 2012-03-22 Instytut Biochemii I Biofizyki Pan Composés modulateurs d'une protéine cftr mutante et leur utilisation pour le traitement de maladies associées à un dysfonctionnement de la protéine cftr
US10016402B2 (en) 2011-02-08 2018-07-10 Children's Medical Center Corporation Methods for treatment of melanoma
WO2020248075A1 (fr) * 2019-06-12 2020-12-17 The Governors Of The University Of Alberta Ciblage de la réparation de l'adn dans des cellules tumorales par inhibition d'ercc1-xpf

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620588B1 (en) * 2000-05-31 2003-09-16 Salk Institute For Biological Studies Method of identifying inhibitors of topoisomerase DNA religation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620588B1 (en) * 2000-05-31 2003-09-16 Salk Institute For Biological Studies Method of identifying inhibitors of topoisomerase DNA religation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WILLIAMSON ET AL.: "The plastid DNA of the malaria parasite Plasmodium falciparum is replicated by two mechanisms", MOLECULAR MICROBIOLOGY, vol. 45, no. 2, 2002, pages 533 - 542 *

Also Published As

Publication number Publication date
WO2006015369A2 (fr) 2006-02-09
WO2006015369A9 (fr) 2006-03-30

Similar Documents

Publication Publication Date Title
WO2006127899A3 (fr) Synthese de (r)-n-methylnaltrexone
WO2005046603A3 (fr) Composes pyridiniques
WO2007022257A3 (fr) Composes monocycliques et bicycliques, et procedes d'utilisation
WO2006078287A3 (fr) Inhibiteurs de pde4b
IL174952A0 (en) Sulfoximine-substituted pyrimidines for use as cdk and/or vegf inhibitors, the production thereof and their use as drugs
WO2007002667A3 (fr) Composés d'azaindazole et procédés d'utilisation
WO2007050793A3 (fr) Methodes et compositions de traitement du syndrome de marfan et de troubles associes
WO2006119295A3 (fr) Compositions et methodes de traitement de maladies neurodegeneratives
WO2006023627A8 (fr) Polymorphes de rapamycine et leurs utilisations
WO2007044885A3 (fr) Derives de piperidine et leurs procedes d'utilisation
IL179227A0 (en) Methods and reagents for the treatment of immunoinflammatory disorders
AP2359A (en) Sulfonamide derivatives for the treatment of diseases.
WO2007056435A3 (fr) Maladies mediees par la dynamine et procedes et produits associes
WO2007051785A3 (fr) Utilisation de sdf-1 pour le traitement et/ou la prevention de maladies neurologiques
WO2006074450A3 (fr) Methodes et compositions permettant de detecter et de moduler les maladies et les troubles parodontaux
WO2006135694A3 (fr) Composes modulateurs d'uii et utilisation
WO2006071812A3 (fr) Inhibiteur de complexe de platine iv
WO2006053315A3 (fr) Methodes et compositions de traitement de maladies proliferatives cellulaires
WO2006015369A3 (fr) Dosage d'identification d'inhibiteurs de topoisomerase
SI1833995T1 (sl) Identifikacija tarč RNA z uporabo helikaz
WO2007038331A3 (fr) Nouveaux composes chimiques
WO2005092062A3 (fr) Composes destines aux troubles neurodegeneratifs
WO2007010013A3 (fr) Composes organiques
WO2005023253A8 (fr) Utilisation d'inhibiteurs de pde4 pour le traitement du diabete sucre
FR2872494B1 (fr) Distributeur de produits fluide ou pulverisant

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/8-8/8, DRAWINGS, REPLACED BY NEW PAGES 1/8-8/8; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11701981

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase
WWP Wipo information: published in national office

Ref document number: 11701981

Country of ref document: US